Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Repare Therapeutics Inc (NQ: RPTX )

2.970 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc

< Previous 1 2 3 4 5 6 Next >
Repare Therapeutics Insiders Establish New and Modified Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate in Two Upcoming Virtual Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Closing of Upsized Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Repare Therapeutics Inc.
Via Business Wire
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In... 
Via Benzinga
Repare Therapeutics Announces Pricing of Upsized Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Announces Proposed Public Offering of Common Shares
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate at the H.C. Wainwright 2nd Annual Precision Oncology Conference
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Reveals Early Efficacy Data From Lead Program In Solid Tumor Setting
Repare Therapeutics Inc (NASDAQ: RPTX) announced the presentation of preliminary Phase 1 monotherapy data from its Phase 1/2 TRESR trial of RP-3500 for solid... 
Via Benzinga
Repare Therapeutics Presents Preliminary Phase 1 Monotherapy Clinical Data from the Ongoing First-in-Human Phase 1/2 TRESR Study of RP-3500 in Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
Via Benzinga
Exposures COVID-19
28 Stocks Moving In Friday's Mid-Day Session
Gainers ChemoCentryx, Inc. (NASDAQ: CCXI) shares climbed 60.8% to $31.51. The FDA approved ChemoCentryx’s Tavneos (avacopan) as an adjunctive treatment for anti-neutrophil... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers ChemoCentryx (NASDAQ:CCXI) shares rose 77.65% to $34.82 during Friday's pre-market session. The company's market cap stands at $2.4 billion. eFFECTOR... 
Via Benzinga
45 Biggest Movers From Yesterday
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial... 
Via Benzinga
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
Repare Therapeutics Issues Statement Regarding Inadvertent Issuance of Phase 1/2 TRESR RP-3500 Clinical Trial Abstract by the AACR-NCI-EORTC Virtual International Conference
From Repare Therapeutics, Inc.
Via Business Wire
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs, And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Here are the key catalysts that could move stocks in the unfolding... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks. Positive tidings from Merck & Co... 
Via Benzinga
Exposures Product Safety
Repare Therapeutics to Present Initial Data from the Phase 1/2 TRESR RP-3500 Clinical Trial at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021
Upgrades Barclays upgraded the previous rating for Warner Music Group Corp (NASDAQ: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2021
Upgrades For Bank of America Corp (NYSE: 
Via Benzinga
Repare Therapeutics Appoints Thomas Civik to Its Board and as New Chairman
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics to Participate at the 19th Annual Morgan Stanley Virtual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Repare Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021
Upgrades For Toll Brothers Inc (NYSE: 
Via Benzinga
Repare Therapeutics to Participate at the 42nd Annual Goldman Sachs Virtual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
Cathie Wood Buys $26M Disney Shares And Sells $13M In Netflix: What You Need To Know
Cathie Wood-led Ark Investment Management on Friday bought 150,556 shares, worth about $26.15 million, in Walt Disney Co (NYSE: DIS), marking its debut in the media and... 
Via Benzinga
Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day
Cathie Wood-led Ark Investment Management on Thursday shed 162,840 shares, worth about $33.6 million, in Alibaba Group Holding (NYSE: BABA) after the company posted its first... 
Via Benzinga
Repare Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
Cathie Wood Piles Up Palantir For Third Day In A Row, Adding $39M Worth Of Shares
Cathie Wood-led Ark Investment Management on Wednesday snapped up 2.07 million shares, worth about $39 million, in Palantir Technologies Inc (NYSE: PLTR), on a day the... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.